Discovery of Orally Available 8-Aza-5-thiaProstaglandin E1 Analogs as Highly Selective EP4 Agonists-Reference-Cited by-同舟云学术

Discovery of Orally Available 8-Aza-5-thiaProstaglandin E1 Analogs as Highly Selective EP4 Agonists

Published:2011 Issue:12 Volume:59 Page:1523-1534
ISSN:0009-2363
Container-title:Chemical and Pharmaceutical Bulletin
language:en
Short-container-title:CHEMICAL & PHARMACEUTICAL BULLETIN

Author:

Kambe Tohru¹,Maruyama Toru¹,Nakano Masayuki¹,Yamaura Yoshiyuki¹,Shono Tomoyuki¹,Seki Akiteru¹,Sakata Kiyoto¹,Maruyama Takayuki¹,Nakai Hisao¹,Toda Masaaki¹

Affiliation:

1. Minase Research Institute, Ono Pharmaceutical Co., Ltd.

Publisher

Pharmaceutical Society of Japan

Subject

Drug Discovery,General Chemistry,General Medicine

Link

http://www.jstage.jst.go.jp/article/cpb/59/12/59_12_1523/_pdf

Reference9 articles.

1. Design and synthesis of a selective EP4-receptor agonist. Part 4: practical synthesis and biological evaluation of a novel highly selective EP4-receptor agonist

2. Lactams as EP4 prostanoid receptor subtype selective agonists. Part 1: 2-Pyrrolidinones-stereochemical and lower side-chain optimization

3. Lactams as EP4 Prostanoid Receptor Agonists. 3. Discovery of N-Ethylbenzoic Acid 2-Pyrrolidinones as Subtype Selective Agents

4. Discovery of a potent and selective agonist of the prostaglandin EP4 receptor

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Catalytic Transfer Vinylation of Alcohols;Advanced Synthesis & Catalysis;2024-07-23

2. Discovery of {4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid (GSK726701A), a novel EP4 receptor partial agonist for the treatment of pain;Bioorganic & Medicinal Chemistry Letters;2018-06

3. Direct C-sp2-H enolization: an allenoate alkylation cascade toward the assembly of multi-substituted furans;ORG BIOMOL CHEM;2017

4. A simple method for the synthesis of furfuryl ketones and furylacetic acid derivatives;Chemistry of Heterocyclic Compounds;2015-07

5. KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration;European Journal of Pharmacology;2015-05